Proteins and Peptides
21 March 2016
XTL Biopharmaceuticals Completes Phase 2 Trial Design for Lead Compound hCDR1 in the Treatment of Lupus16 March 2016
Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine7 March 2016
New Data Released on EVARREST® Fibrin Sealant Patch as a Hemostatic Adjunct in Aortic Reconstruction Surgery5 March 2016
Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial29 February 2016
Thrasos Announces Promising Results for Phase 2 THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI)26 February 2016
Baxalta Announces Submission of Supplemental BLAs to Expand Use of ADYNOVATE to Pediatric Patients and Surgical Settings26 February 2016
Sobi and Biogen receive positive opinion from CHMP for Alprolix® (rFIXFc) for the treatment of haemophilia B24 February 2016
Merganser Biotech Inc. Initiates First Clinical Trial23 February 2016
OPKO Health Announces Dosing of First Patient in Phase 2a Clinical Study of a Long-Acting Factor VIIa for the Treatment of Hemophilia23 February 2016
Novo Nordisk successfully completes fifth phase 3a trial with semaglutide in people with type 2 diabetes23 February 2016
Ranpirnase Exhibits Anti-Zika ActivityNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports